In re of Appln. No. 10/642,289 Reply dated: June 1, 2005 In reply to OA dated March 25, 2005

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:
Listing of Claims:

- 1. (original) An isolated protein or derivative, analogue, chemical equivalent or mimetic thereof wherein said protein is a novel sphingosine kinase protein.
- 2. (original) An isolated protein according to claim 1 wherein said sphingosine kinase protein is a human sphingosine kinase protein.
- 3. (original) An isolated protein comprising an amino acid sequence substantially as set forth in SEQ ID NO:2 or a derivative or mimetic thereof or a sequence having at least about 45% similarity to at least 10 contiguous amino acids in SEQ ID NO:2 or a derivative, analogue, chemical equivalent or mimetic of said protein.
- 4. (original) An isolated protein according to claim 3 encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:1 or a derivative or analogue thereof or capable of hybridising to SEQ ID NO:1 under low stringency conditions or a derivative, analogue, chemical equivalent or mimetic of said protein.

- 2 -

In re of Appln. No. 10/642,289 Reply dated: June 1, 2005 In reply to OA dated March 25, 2005

- 5. (original) An isolated protein according to claim 1 substantially as set forth in SEQ ID NO:2.
- 6. (original) Sphingosine kinase or sphingosine kinase or a derivative, analogue, chemical equivalent or mimetic thereof for use in modulating cellular functional activity.
- 7. (currently amended) A pharmaceutical composition comprising sphingosine kinase, sphingosine kinase or an agent capable of modulating sphingosine kinase or sphingosine kinase the sphingosine kinase of claim 1 or derivative, homologue, analogue, chemical equivalent or mimetic thereof together with one or more pharmaceutically acceptable carriers and/or diluents.
- 8. (new) A pharmaceutical composition comprising the sphingosine kinase of claim 2 or derivative, homologue, analogue, chemical equivalent or mimetic thereof together with one or more pharmaceutically acceptable carriers and/or diluents.
- 9. (new) A pharmaceutical composition comprising the sphingosine kinase of claim 3 or derivative, homologue, analogue, chemical equivalent or mimetic thereof together with

In re of Appln. No. 10/642,289 Reply dated: June 1, 2005 In reply to OA dated March 25, 2005

one or more pharmaceutically acceptable carriers and/or diluents.

- 10. (new) A pharmaceutical composition comprising the sphingosine kinase of claim 4 or derivative, homologue, analogue, chemical equivalent or mimetic thereof together with one or more pharmaceutically acceptable carriers and/or diluents.
- 11. (new) A pharmaceutical composition comprising the sphingosine kinase of claim 5 or derivative, homologue, analogue, chemical equivalent or mimetic thereof together with one or more pharmaceutically acceptable carriers and/or diluents.
- 12. (new) A pharmaceutical composition comprising the sphingosine kinase of claim 6 or derivative, homologue, analogue, chemical equivalent or mimetic thereof together with one or more pharmaceutically acceptable carriers and/or diluents.